Company Monitoring Page for Dyax

latest headlines for company on cafepharma

Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application
Endpoints
Thu, 05/18/17 - 09:38 am
Tags:
Shire, lanadelumab, DX-2930, HAE, Cinryze, Dyax
Shire Completes Acquisition of Dyax
Yahoo
Fri, 01/22/16 - 10:06 am
Tags:
Shire, Dyax, M&A
Biotech Investing: This Is Undoubtedly the Craziest Stat You'll Ever See
Motley Fool
Sat, 01/16/16 - 11:41 am
Tags:
biotech, Dyax, Baxalta
Dyax shares jump as antitrust waiting period for Shire acquisition ends
Marketwatch
Thu, 12/3/15 - 09:29 am
Tags:
Dyax, Shire, M&A
$5.9 Billion Buyout: 1 Number Underpins Shire's Huge Dyax Bet
Motley Fool
Sat, 11/7/15 - 12:45 pm
Tags:
M&A, Dyax, Shire
5 BioPharma Movers That Cannot Be Ignored
24/7 Wall St
Sat, 11/7/15 - 11:38 am
Tags:
MannKind, ZS Pharma, Xoma, Dyax, Valeant Pharmaceuticals
Shire to Acquire Dyax for $5.9 Billion to Bolster Rare Disease Drug Business
TheStreet.com
Mon, 11/2/15 - 08:10 am
Tags:
Shire, Dyax, M&A
Dyax banks on drug designation news
Bizjournals.com
Tue, 07/7/15 - 12:28 pm
Tags:
Dyax, DX-2930, HAE, hereditary angiodema
Dyax's Threat to $630,000 Shire Drug Makes It a Target
Bloomberg
Thu, 06/11/15 - 10:13 am
Tags:
Shire, Dyax, DX-2930, HAE, hereditary angiodema, Cinryze
Dyax shares jump on drug study, FDA fast-track status
Marketwatch
Tue, 03/31/15 - 05:53 pm
Tags:
Dyax, FDA, fast track, DX-2930, hereditary angiodema
3 Surging Biotech Stocks to Watch: OncoSec, Clovis, Dyax
Wall St Cheat Sheet
Mon, 03/3/14 - 03:33 pm
Tags:
OncoSec, Clovis Oncology, Dyax
This Company Is Focused on Delivering Value to Patients and Shareholders
Motley Fool
Sun, 10/6/13 - 09:19 am
Tags:
Dyax, DX-2930, angioedema
The Best- And Worst-Performing Biotech Stocks, June 28 to July 5
Forbes
Mon, 07/8/13 - 11:02 am
Tags:
biotech, ONYX Pharmaceuticals, Celldex, Novavax, Puma Biotechnology, Endocyte, Alnylam, Bluebird Bio, Dyax, Medivation, Clovis Oncology, Achillion, Insmed, Arena Pharmaceuticals, Avanir, Receptos, Synergy Pharmaceuticals, ChemoCentryx, Idenix, MiMedx, Portola Pharmaceuticals
An Interesting Bio Play in the Blood Disorder Niche
Motley Fool
Tue, 07/2/13 - 01:39 am
Tags:
hereditary angiodema, Dyax, Shire, CSL, ViroPharma, Biovitrum, Halozyme, Cinryze
[video]3 Biggest Biotech Crashes in April
Motley Fool
Thu, 05/2/13 - 10:36 am
Tags:
Dyax, Rigel Pharmaceuticals, Sarepta, AstraZeneca
ViroPharma: Generic Concerns Overblown, Pipeline Will Bring Revenue Diversity
Seeking Alpha
Wed, 04/3/13 - 10:55 am
Tags:
ViroPharma, Dyax, Shire, Halozyme, generics
Pending Q4 Results: Dyax Partnerships Could Yield Sustained Growth For Investors
Seeking Alpha
Fri, 02/8/13 - 12:03 pm
Tags:
Dyax
Dyax And ViroPharma: An Overview Of HAE Space
Seeking Alpha
Wed, 09/19/12 - 10:58 am
Tags:
ViroPharma, Dyax, Cinryze, hereditary angiodema, Kalbitor
Dyax announces partnership with taiba for Kalbitor
The Fly on the Wall
Tue, 06/5/12 - 12:13 pm
Tags:
Dyax, Kalbitor, hereditary angiodema, Middle East, taiba ME
Shire Enters a Crowded Market
Motley Fool
Thu, 09/1/11 - 11:37 am
Tags:
Shire, Firazyr, Dyax, angioedema, CSL

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.